Trial Profile
Adoptive Cell Therapy Across Cancer Diagnoses
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
- Indications Cancer; Cholangiocarcinoma; Head and neck cancer; Sarcoma
- Focus Adverse reactions
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 21 Sep 2020 Results from clinical trials ( NCT03287674 and NCT03296137) presented at the 45th European Society for Medical Oncology Congress
- 10 Aug 2020 Planned End Date changed from 6 Jun 2020 to 30 Sep 2020.